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Tomasz RutkowskiAbstract
The assumption that the larger tumor contains a higher number of clonogenic cells what may deteriorate
prognosis of patients treated with RT has been confirmed in many clinical studies. Significant prognostic influence
of tumor volume (TV) on radiotherapy (RT) outcome has been found for tumors of different localizations including
patients with head and neck cancer (HNC). Although TV usually is a stronger prognostic factor than T stage,
commonly used TNM classification system dose not incorporate TV data. The aim of the paper is to refresh clinical
data regarding the role of TV in RT of patients with HNC. At present somehow new meaning of TV could be
employed in the aspect of modern RT techniques and combined treatment strategies. For larger TV more
aggressive treatment options may be considered. In modern RT techniques escalated dose could be provided
highly conformal or RT can be combined with systemic treatment increasing therapeutic ratio. In the study several
reports estimating prognostic value of TV for patients with HNC treated with RT has been reviewed.
Due to substantially various reported groups of patients as to tumor site, stage of disease or treatment strategies,
precise cut-off value could not be establish in general, but the significant association between TV and treatment
outcome had been found in almost all studies. There is a strong suggestion that TV should supplement clinical
decision in the choice of optimal treatment strategy for patients with HNC.
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One of the principles of modern radiation biology is that
a higher radiotherapy (RT) dose is needed to sterilize a
higher number of clonogenic cells in larger tumors. The
requirement for increased radiation dose for larger tu-
mors is related also to other factors like hypoxia, clonal
radioresistance or intercellular communication. While
these factors are difficult to predict for given tumor, it
has been reported that clonogen number increases
linearly with the tumor volume (TV) [1,2]. In accord-
ance to the theory, TV has been reported as an import-
ant factor influencing RT outcome of patients with
various types of tumors including head and neck cancers
(HNC). The commonly used TNM classification system
for HNC does not reflect TV, incorporating linear di-
mension only for few tumor localizations. Compared to
other known tumor response predictors, the TV appearsCorrespondence: tomr22@tlen.pl
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reproduction in any medium, provided the orto be specific and relatively easy to obtain. Modern radi-
ation oncology requires the use of various imaging mo-
dalities to adequately identify and delineate the TV
usually surrounded by normal anatomic structures.
Along with this, improvement in segmentation algo-
rithms and advances in computed technology occurred,
giving the possibility for routine TV assessment. Due to
precise estimation, TV may serve as a additional pre-
dictor for the choice between more and less aggressive
treatment strategy.
At present somehow new meaning of TV could be
employed. Modern RT techniques or combined treat-
ment strategies (radiochemotherapy – CHRT) that could
intensify therapy should be considered for patients with
large TV. The aim of the paper is to refresh clinical data
regarding the role of TV in RT of patients with HNC.
Several studies on this matter has been reviewed and
discussed.d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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A computer literature search in MEDLINE was per-
formed. For this purpose the following free-text terms
were used: ‘Tumor volume’ or ‘Primary tumor volume’
or ‘Head and neck cancer/carcinoma’ or ‘Volumetric sta-
ging’, or ‘Volumetric analysis’. Additionally, extensive
hand-searching of the references of all relevant studies
was also performed.
TV and TNM staging system
The stage of cancer at the time of diagnosis is crucial
factor defining prognosis and remains the essential
element in determining appropriate treatment based on
the experience and outcomes of groups of prior patients
with similar stage. In addition, according to AJCC, ac-
curate staging is necessary to evaluate the results of
treatments and clinical trials, to facilitate the exchange
and comparison of information among treatment centers
and to serve as a basis for clinical and translational can-
cer research [3]. The TNM system classification of ma-
lignant tumors was developed by Pierre Denoix between
1943 and 1952. It was originally constructed to assess
only three basic indicators of anatomical spread: local
tumor extent (T), locoregional nodal spread (N) and dis-
tant metastases (M). As outlined in Purposes and Principles
of Cancer Staging 7th, although anatomic extent of disease
remains central to defining cancer prognosis, an increasing
number of nonanatomic factors about cancer and its host
provide critical prognostic information and may predict
the value of specific therapies. Revised AJCC staging algo-
rithms gradually incorporate such factors. The TV seems
to be one of nonanatomical factors representing properties
of the tumor and showing significant impact on radiother-
apy outcome but still not included to the classification
system. Fundamental goal for radical (not palliative)
radiotherapy is to kill the last surviving cancer cell,
otherwise if one cell would survive local failure may
likely be expected and therefore all of the dose would
be wasted. Logically, total dose and its fractionation
should be tailored to the initial number of tumor cells
which strongly correlated with tumor volume (TV) ra-
ther than to the tumor diameter or stage T. If tumor
diameter doubles (e.g. 1 to 2 cm or 2 to 4 cm) its
volume increases by 8 fold and cell number increases
by about one decade respectively. Design of dose frac-
tionation for individual tumor depends on clinical, and
recently more and more often, on molecular profile al-
though TNM stage still plays the major role. However,
there is relatively large variation of TVs within a given
T stage N0M0 and it seems suboptimal to prescribe the
same total dose to all tumors within a single T category.
Several authors have noted that TV is even better pre-
dictor of treatment outcome than TNM system or AJCC
clinical stage [4-7]. Currently only about half of headand neck malignant tumors subsities are T-classified
with the consideration of tumor dimension. In these
cases the classification is based on a single dimensional
measurement only. Such surrogate for TV seems to be
not adequate. It was found that the difference in TV de-
rived from diameter measurement and the computed-
assisted perimeter method is large enough to have an
impact on the response of the therapy [8]. Furthermore,
staging based on single dimension measurement may be
insufficient due to various clinical appearance of the
tumor. The large tumor of epiglottis involving base of
the tongue ((…) tumor invading mucosa of the region
outside the supraglottic without fixation of the larynx)
would be classified as T2. Small tumor of the glottis may
infiltrate and destroy thyroid cartilage being classified as
T4. Under the assumption that the number of tumor
clonogens increases in direct proportion to TV [2] it
seems to be clear that the second tumor, although T4,
would be easier eradicated by radiation than previous
one. With tumors staged clinically as T2 and T3 only
39% agreement between clinical and radiographic T
stage was found by Kraas et al. [9]. The considerable
variability of TV in a single T-stage category has been
reported. Pameijer at al. found that among T3 tumors
of different localization in head and neck region, TV
variability was striking with variation exceeding 100%.
Reported TVs for laryngeal, oropharyhngeal, hypophar-
yngeal tumors in T3 stage were from the range of 1.7-
17 cm3, 10-41 cm3, 8.9-67.8 cm3 respectively. Moreover,
the TV of T3 larynx and hypopharynx carcinoma
showed a highly significant difference although the
main TNM criterion for defining T3-stage in these sub-
sities is the same, that is, vocal cord fixation. Much
larger range of TV was reported for larynx and hypo-
pharynx carcinoma defined by anatomical extent than
for the oropharynx carcinoma which is defined by max-
imum diameter [10].
In the group of almost two hundred patients with T4
HNC of various sites with the mean TV of 64 cm3,
Studer et al. used staging system based on three cut-
offs to stratified TV and found it highly statistically sig-
nificant for prognosis of RT outcome [11]. For T3 and
T4 oropharyngeal tumors the TV ranges of 0-48 cm3
and 6.5-99.9 cm3 respectively were found [12]. The
considerable range of TV inside the single T-stage is
also true for early disease and generally smaller tu-
mors. For 160 patients with T2 laryngeal tumors the
range of TV from 0.15 cm3 to 21.68 cm3 has been re-
ported [13]. For T1 and T2 hypopharyngeal tumors TV
ranges were respectively as follows: 0.5-3.02 cm3 and
1.13-9.38 cm3 [14]. The TV range of 0-32.5 cm3 for T2
oropharyngeal tumors was observed [12]. For 125 pa-
tients with T2 nasopharyngeal carcinoma the TVs were
from 1.4 cm3 to 60.4 cm3 [15].
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system is that it categorizes tumors with different
volumes into the same stage. Use the pure anatomic
extent of disease in defining treatment for patients with
HNC seems to be not sufficient in many cases and
clinicians should supplement therapeutic decision about
optimal treatment with TV data.
TV measurement
Two-dimensional approach to radiotherapy, CT beyond
the rich in daily clinical practice or variation in TV
measurement techniques have prevented TV assessment
procedure from being routinely used in a clinical setting
in the past. Modern radiation oncology is based on
intensity-modulated radiation beam that may precisely
sculpt the radiation dose to target volumes of almost any
shape. In this framework computed tomography (CT)
has become the reference imaging modality for treat-
ment planning. It has intrinsic information on the elec-
tronic density of the various tissues, which is used for
dose calculation algorithms. It is also widely available
and does not cause geometric distortion. Due to that,
pretreatment contrast-enhanced CT scans are the most
common support for TV assessment. Some limitation of
CT however should be mentioned: uncertainty in precise
tumor delineation on CT scans usually associated with
motion artifacts, crudeness of volume estimation given
large slice thickness, presence of dental fillings or inher-
ent difficulty in differentiating tumor from oedema or
biopsy changes. In retrospective studies up to 40% exclu-
sion rate of CT scans due to uncertainties in CT quality
has been reported [16]. The degree of motion artifacts
may be influenced by patient-controlled factors such as
swallowing, coughing, breathing manner or movement.
Due to technological advancement of multidetector spiral
scanners less motion artifacts and potentially thinner
slices could be obtained. Technical aspects of obtaining
CT scans may differ for various tumor localization. For
early stages of laryngeal tumors it is important to align
properly the CT cuts with anatomic landmarks to be in
plane with the true vocal cords.
The volumetric analysis depends on a hand-drawn re-
gion of interest. Whether this process is performed by
radiologist, radiooncologist or technician, the element of
subjectivity could not be avoid. This is an issue for poten-
tial interobserver and intraobserver error. To minimize
this inaccuracy, the measurement should be done by sin-
gle, trained observer [17]. The inter- and/or intra-operator
variability is tried to be overcome also by semi-automated
or automated systems. Errors encountered by computered
based techniques exclude the problem of operator experi-
ence and are classified as systemic errors.
The definition of tumor boundaries on CT may carry
on some difficulty in precise because separation theoedema and tumor from each other is complex. Usually
the area of peritumor oedema is excluded from the re-
gion of interest (TV), but also no attempt to differentiate
these two areas has been reported [18]. MR imagining,
although not effective in differentiating edema form tu-
mors, is more sensitive than CT in distinguishing tu-
mors (together with peritumoral edema) from normal
adjacent structures. MR also has been shown to be more
accurate than CT in evaluating soft-tissue or bone ex-
tension [19]. It seems to be of special concern for some
tumor sites (nasopharynx) where exclusion of invasion
into the skull base may be essential. For oropharyhngeal
and hypopharyngeal cancers primary TVs showed by CT
and MR imaging did not exhibit significant differences
[20]. MR does not carry any intrinsic information on
electronic density mapping what precludes its use as the
sole imaging modality for treatment planning.
Unlike CT and MR, fluorine 18 (18 F) fluorodeoxyglu-
cose (FDG) positron emission tomography (PET) pro-
vides not only anatomy imaging but also non-invasive
functional one, reflecting functional and biological me-
tabolism. For treatment planning purposes, it was shown
that the combined use of CT and FDG PET in lung tu-
mors resulted in an improved delineation of the TV sub-
stantially reducing the irradiated lung volume [21]. PET
does not provide any accurate information on the con-
tours of the infiltration what precludes its use as a sole
imaging modality for HNC treatment planning. Together
with CT incorporates both, anatomic localization and
functional information.
The results from recent studies of HNC indicate that
high FDG uptake in the primary tumor, typically charac-
terized as a standardized uptake value (SUV) may pre-
dict treatment outcome [22]. It is not clear however at
that time, if higher SUV, greater than median one, or
metabolic TV, tend to be better predictor [22,23]. It ap-
peared that if TV is contoured in the pharyngolaryngeal
area on CT scans, MRI scans and PET images, no sig-
nificant difference between TV obtained at two first
techniques is observed. The TV assessed by PET is
smaller with the difference from 28% to 37% comparing
to CT and MRI. Non of these TVs is totally overlapped
with each other. Only up to 20% of the TV assessed from
anatomic imagine (CT, MRI) could be observed with
PET. Of interest, in comparison with surgical specimen
of previously scanned tumors used as a reference, all the
imaging modalities overestimated the original TV [20].
TV and treatment results
Prognostic cut-off values for TV stratification
In most series cut-off levels of TV were based on object-
ive criteria as a mean or quartiles (median) [13,24-26] or
on subjectively estimated values of TV, also called “opti-
mal cut-off” [9,14,18,27-30] or ranges of these values
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of the tumor determines TV as well. For laryngeal tu-
mors cut-off values from the range of 4-6 cm3 were
the most often used [9,18,30]. Hermans et al. stratified
TV of glottic cancer for 5 classess (<1 cm3, 1-2 cm3,
2-4 cm3, 4-8 cm3, 8-16 cm3) [31] and supralaryngeal
cancer for classes each 2 cm3 (range: <2 cm3 - >16 cm3)
[32]. For relatively large series of 160 patients with T2
laryngeal cancer, median TV for those with supraglot-
tic tumors was significantly higher than for glottic
onces (5.5 cm3 v 0.8 cm3, p < 0.0001). For analysis, TV
in that series was stratified according to quartiles [13].
Pamijer et al. stratified TV of patients with early hypo-
pharyngeal tumors by optimal cut-off value of 6.5 cm3
[14]. For nasopharyngeal cut-off value of 15 cm3 was
often used [15,34]. Hermans et al. stratified tonsillar tu-
mors in volume classes according to the quartiles: <6 cm3,
6-14.5 cm3, 14.5 – 31.2 cm3, >31.2 cm3) [25].
Reported thresholds of TV were also depended on
treatment modality – usually larger for CHRT (>20 cm3)
than for RT alone. The median value of 32.79 cm3 was
used to stratified risk in patients with advanced orophar-
yhngeal cancer treated with CHRT [27]. Studer et al. for
similar group of patients used four volume cut-offs: 1-
15 cm3, 16-70 cm3, 71-130 cm3, >130 cm3 [11]. Others
used TV from the range of 22.8-112 cm3 for stratifying
the risk of patients with advanced tumors of various
localization treated with CHRT [6,7,24,26,28,29].
TV and RT treatment outcome
Most of the volumetric studies in patients with HNC
have been reported for small groups of patients mixed as
to tumor site, stage or treatment methods. Kraas et al.
reported 28 patients with supraglottic cancer in various
T- stage treated with RT. Median TV was 3.1 cm3 in this
group. Local control (LC) rate at 2 years were 67% and
43% for TV cut-off at 6 cm3 (p = 0.07) and 20% and 70%
for TV cut-off at 8 cm3 (p = 0.007). Mean tumor vol-
umes for patients with or without recurrences were
10 cm3 and 3.4 cm3 respectively. Pre-epigoltic space
invasion, subsite of disease or vocal cord mobility
were not found to have an impact on local control rate
[6]. Mancusco et al. in a study of 63 patients with T2-
T4 supraglottic cancer found LC rates of 89% and 52%
(p = 0.001) when tumors were less than 6 cm3 or ≥6 cm3,
respectively. Moreover, the likelihood of maintaining
laryngeal function also varied with TV: 89% for tumor less
than 6 cm3 and 40% for tumors ≥6 cm3 (p < 0.001) [18].
Hermans et al. reported a significant correlation between
TV classes and local control within the glottic T1 category
(p = 0.006) in the group of 61 patients with T1-T4 glottic
tumors [31]. In a group of 47 patients with T2-T3 glottic
or supraglottic cancer reported by Hamilton et al. the TV
ranged from 0.2 cm3 to 16.64 cm3 with the mean of3.5 cm3. For all the group, those with TV of less than
3 cm3 recurred in only 22% of cases whereas there
was a 65% recurrence rate in tumors greater than
3 cm3 (p = 0.003). For glottic cancer such cut-off value
was at TV of 1 cm3. T-stage, preepiglottic space inva-
sion, tumor location (glottic vs supraglottic) or vocal cord
mobility were not found to correlate with local recurrence
rate [35]. The TV implications was reviewed also in the
group of 55 patients with T2,T3 either glottic or supraglot-
tic cancer treated with RT or surgery. The TV >4 cm3 was
a predictor of local failure in the subgroup of T2 patients
treated with RT. This volume effect was not abolished
with increasing radiation dose. No TV was identified to be
a predictor of locoregional control in the group of patients
surgically treated. T and N stage were not independent
predictors of tumor control [30]. Mukherij et al. reported
results of 28 patients with T2 glottic cancer. The study is
one of few where the relationship between TV and RT
outcome for laryngeal tumors was not found [36].
Contrary to this, the strong correlation between TV
and RT outcome was found in the group of 115 pa-
tients with T2 glottic cancer treated exclusively with RT
between 2002 and 2009. There was considerable, 10
folds difference between the smallest and the largest
TV within a single, T2 classified tumors (median:
2.2 cm3, range: 0.16 – 17 cm3). Six time increase in the
TV resulted in more than 3 time decrease in the LC.
For TV ≤0.7 cm3 3-year LC was 83%, 70% for TV of
0.7-3.6 cm3 and 44% for TV of 3.6-17 cm3 respectively.
Independently of other factors, tumors with TV larger
than 1.6 cm3 had significant, 3 times higher risk of local
failure than smaller ones (HR 3.21, 95% CI 1.07 – 9.63,
p = 0.03). Analysis of the total dose vs. initial TV has
shown that within the T2 glottic cancer larger tumors
with TV of about 5 cm3 (2-2.5 cm in diameter with
1010 cancer cells) need an extra 6.5 Gy to achieve simi-
lar 3-year LC as small tumors with 0.5 cm3 (~1 cm in
diameter with 109 cancer cells) [37]. Hermans et al. re-
ported on 103 patients treated with definitive RT for
supraglottic cancer. TV significantly influenced local
control in univaraite analysis but in multivariate one,
only pre-epiglottic space invasion and subglottic exten-
sion were found to by significant. TV was however the
strongest independent predictor of locoregional failure
(p < 0.01) [32].
Pameijer et al. reported on 23 patients with T1 and T2
carcinoma of the pyriform sinus treated with definitive
RT between 1984 and 1993. Local control was observed
in 89% of patients with TV ≤6.5 cm3 compared with 25%
for patients with TV >6.5 cm3 (p = 0.02) [14].
There were only few studies considering TV in pa-
tients with oropharyngeal cancer treated exclusively with
RT showing conflicting results. Studer et al divided large
group of 277 patients with oropharyngeal cancer who
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ing to TV (1-15 cm3, 16-70 cm3, 71-130 cm3, >130 cm3).
Such volumetric staging appeared to be the most reliable
in predicting treatment outcome in that group of T4 pa-
tients [38]. Hermans et al reported on 112 patients with
tonsilar squamous cell carcinoma treated with definitive
RT before 2001. TV was found to predict local control
significantly when stratified by quartiles but not within
T2-T4 stages. Multivariate analysis revealed that T stage
significantly impacted local control whereas TV did not
[25]. In another series result of analysis of 114 patients
with T2-T4 oropharyngeal cancer treated between 1983
and 1995 with definitive RT or additionally with induction
chemotherapy was reported. Multivariate analysis revealed
that TV did not influence local control but T-stage signifi-
cantly impacted this end point [12].
Also for nasopharyngeal carcinoma TV appeared to be
significantly related to RT results. In the group of 308
patients with the median TV of 22 cm3, 3-year LC was
97% and 82% for patients with TV <15 cm3 and ≥15 cm3
respectively (p < 0.01). The TV remained an independent
prognostic factor for the LC in multivariate analysis with
the increase by 1% for every 1 cm3 increase in TV [15].
Sixty seven patients with T1 and 49 patients with T2 naso-
pharyngeal carcinomas treated with definitive RT between
1989 and 1991 were reported with the respect to TV. The
median TV was 7.6 cm3 and 22.7 cm3 for these groups re-
spectively. The 5-year local control rates were 93% and
82% for those with tumor ≤15 cm3 and >15 cm3 respect-
ively [34].
TV and CHRT treatment outcome
Definitive CHRT has become a common option for the
treatment and accepted as a method of organ preserva-
tion for patients with locally advanced HNC. This com-
bined modality treatment has been associated with
greater rates of toxicity. Careful patient selections seems
to be crucial to optimize the therapeutic ratio for such
modality. The TV measurement may provide valuable
information to guide treatment decision. The potential
goal of using TV as an outcome predictor is to identify
patients who are unlikely to benefit from CHRT. These
patients can be spared the intensive, toxic CHRT treat-
ment regimes or can be considered for alternative treat-
ment options (induction CHT, altered fractionation RT
or combination of RT with other drugs like monoclonal
antibodies or hypoxic cell radiosensitizers). The TV as-
sessment may also help stratifying patients for clinical
trials. For the group of patients for whom a favorable re-
sponse is predicted, strategies can be developed to de-
crease toxicity and side effects. The prognostic value of
TV for such patients has been reported by some authors
and shows that the TV is a better predictor of outcome
than either T or N stage. In a group of 78 patients withlocally advanced carcinoma of larynx or pharynx the
TV of 35 cm3 was found as an optimal cut-point. Sev-
enty one percent of patients with a TV <35 cm3 were
tumor-free at 5 years compared with only 41% of pa-
tients with TV >35 cm3 (p = 0.01). The 5-year overall
survival (OS) rate for patients with TV <35 cm3 was 84%
vs. 42% for the patients with TV >35 cm3 (p < 0.001). Simi-
larly, the 5-year progression-free survival for patients with
TV <35 cm3 was 61%, but it was only 33% for those with
TV >35 cm3 (p = 0.01). On multivariate analysis TV
remained statistically significant predictor of progression-
free survival and OS while T and N stage did not. Neither
the nodal disease volume nor the total sum of all disease
(primary and nodal) was a statistically significant prognos-
tic factor [7]. Chen et al. found that for patients with ad-
vanced stages of hypopharyngeal tumors without bulky
lymph nodes treated with definitive CHRT, TV less than
30 cm3 form a favorable group for which definitive CHRT
with laryngeal preservation scheme may be suitable [29].
In another study patients with oropharyhngeal tumor
(mean TV: 24 cm3) had significantly better 3-year locore-
gional control comparing to patients with oral cavity
tumor (mean TV: 41 cm3) (p = 0.01). For all the group
the threshold TV value was 23 cm3 (median value).
Three year rates of locoregional control were 81% and
48% for TV <23 cm3 and ≥23 cm3 (p = 0.03). At the
multivariate analysis the TV remained an independent
determinant of LC and OS while T-stage did not. For
each 10 cm3 increase in TV, the relative risk of locore-
gional failure increases with about 30% [24]. In a
Greek-German collaborative study by Kurek et al. the
TV was negatively associated with survival with an in-
crease in the relative risk of 6% per 10 cm3. Also in this
study pretherapeutic TV was prognostic while TNM
classification was not [39]. Plataniotis et al. presented
prognostic impact of tumor volumetry in slightly differ-
ent way reporting the significant influence of total gross
tumor volume TGTV (primary gross TV (PGTV) +
nodal tumor). For the whole group of patients, the me-
dian PGTV was 14.7 cm3, median nodal tumor was
3.7 cm3 and median TGTV was 25.8 cm3. A prognostic
threshold was detected at 22.8 cm3. Patients with a TGTV
of < 22.8 cm3 were more likely to achieve a completely re-
spond and had a median survival of 45.3 months, and
those with a TGTV >22.8 cm3 had a median survival of
12.3 months (p = 0.01) [28].
Probably the largest study reporting prognostic value
of TV involved 360 patients with advanced HNC treated
with CHRT. The median TV was 28.7 cm3. There was a
significant effect of TV on LC and OS in multivariate
analysis. The HR for the local recurrence and OS in-
creased by 14% per 10 cm3 volume increase. T-stage
remained not significantly related to treatment outcome
status. The TV of 30 cm3 was discussed as the proposal
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a tool for individualizing treatment [6]. The large group
of 340 patients with oropharyngeal cancer was reported
by Lok et al. The majority of patients underwent CHRT.
In univariate analysis TV and T-stage significantly corre-
lated with local failure. On multivariate analysis both TV
and N-stage were independent risk factors for overall
survival and distant control [27].
Early prediction of potential treatment failure after
CHRT is an important goal, as salvage surgery or radio-
surgery may be the only subsequent curative option and
should be performed as early as possible. Bhatia et al.
assessed the prediction of TV based on MRI examin-
ation performed at diagnosis, two weeks into and 6
weeks after CHRT on treatment outcome in 69 patients.
Those with local failure had higher TV comparing to
those with local remission at diagnosis (p = 0.01), 2
weeks into CHRT (p = 0.009) and 6 weeks after CHRT
(p < 0.0001). Patients with local failure had smaller per-
centage reduction in TV 2 weeks into CHRT (p = 0.02)
and 6 weeks after CHRT (p = 0.001). Authors concluded
that TV based on MRI 6 weeks after completing CHRT
is most predictive of local failure and, although can not
be used to modify treatment, it could be important for
selecting patients for more aggressive monitoring [40].
Prediction of regional spread
Few authors found that the regional control is well pre-
dicted by TV [5,41]. Studer et al. found that 2-year
nodal control was 95%, 90% and 75% for the following
TV ranges: 1-15 cm3, >15-70 cm3 and >70 cm3 respect-
ively (p = 0.04) [5]. Certainly there is a correlation
between TV and the risk of nodal metastases. It was
confirmed that patients with pharyngeal tumors [42] and
laryngeal tumors [13] presenting nodal metastases had
significantly higher TV as compared those without nodal
involvment. No such correlation was found for patients
with oral or maxillary sinus cancer [42]. It was also
found that for T2 epiglottic cancer the risk of nodal
spread increase rapidly with TV, doubling for TV be-
tween 2.57 cm3 and 5.62 cm3, and may reach 80% for
large TV (>9.70 cm3) [Rutkowski, unpublished data].
Prediction of distant metastases
Some data indicate that larger TV may increases the risk
of distant spread of disease. Suwinski et al. re-analyzed
several numerical data of TV and the risk of developing
metastases that had been published in the literature
(8707 cases). The results indicate that there is a thresh-
old TV and if exceeded, the risk of developing metasta-
ses raises proportionally to the logarithm of its volume
that is proportionally to the number of TV doublings.
The steepest increase in the incidence of metastases per
one TV doubling corresponds to TV related to about50% incidence of metastases. In homogenous sub-groups
of tumors of a particular histological type, the threshold
curves for the incidence of metastases as a function of
TV are steep and small increase in TV may cause large
increase in the risk of metastases [43]. Studer at al. re-
ported that distant spread was significantly predicted by
TV, while non-significantly stratified by the T-classification
or AJCC staging. Eighty eight per cent of distant metasta-
ses appeared in patients with TV >70 cm3 [5]. In another
analysis of that group of patients where the criterion of
prediction was tested particularly for distant metastases,
TV was the strongest predictor of it. Using similar thresh-
old as in previous study, distant metastases appeared in 4%
and 25% of patients respectively in those with tumors
smaller and larger than 70 cm3 [33]. Strongin et al.
found that patients with locoregional failure had TVs
an average of 27.1 cm3 larger than the TV of patients
whose first site of failure was metastatic disease
(58.0 cm3 vs. 31.0 cm3 p = 0.01) [7]. In the large series
of 360 patients treated with CHRT the HR for distant
metastases increased by 14% (95% CI, 5-24) per 10 cm3
TV increase [6].
Relations between TV and other prognostic and
predictive factors
Although there is an evidence that tumor hypoxia ad-
versely affects locoregional tumor control and survival
in HNC patients it is still not well established how hyp-
oxic fraction of the tumor could be measured. Results of
some studies suggest that TV may, in some way, predict ef-
fectiveness of RT both, reflecting status of tumor oxygen-
ation and correlating with hemoglobin (Hb) concentration.
Hb concentration is well recognized prognostic factor
for HNC patients treated with RT. Among other as-
sumptions, it has been proposed that Hb is a surrogate
marker for tumor hypoxia but still few data exist to test
this hypothesis. Nordsmark et al. found both, Hb and
tumor hypoxia as significant but independent prognostic
factors for locoregional tumor control for HNC patients
after RT, and Hb concentration was not a surrogate
marker of tumor hypoxia [44]. Rutkowski et al. de-
scribed significant negative correlation between TV and
Hb concentration both, before and after RT in 160 pa-
tients with T2 laryngeal cancer [13]. Stadler et al. tried
to reevaluate the prognostic significance of the classical
oxygenation parameters like hypoxic fraction, percentage
of pO2, median pO2. Additionally, he defined a new
radiobiological factor – hypoxic TV (hTV) as the per-
centage of pO2-value below 5 mmHg multiplied by the
TV. The rational of this parameter was to quantify ap-
proximately the amount of hypoxic tissue which should
be correlated to the total number of hypoxic cells in the
tumor. Pretreatment pO2 was assessed in 59 patients
with HNC who underwent RT or CHRT. Results
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mined by the hTV influenced the prognosis of patients
suffering from HNC. In this study significant correlation
between Hb concentration and TV was also found [45].
Continuing this idea, Dunst et al. defined nonhypoxic
TV as a difference between the TV and hTV. It appeared
that patients who were alive at analysis had significantly
lower mean TV: 34 cm3 v 54 cm3 (p = 0.01) and mean
hTV: 11 cm3 v 22 cm3 (p = 0.009) than those who died.
In a multivariate analysis the hTV was strong and inde-
pendent prognostic factor for survival (p = 0.001) and
more important than TV (p = 0.02) whereas the nonhy-
poxic TV had no impact on prognosis (p = 0.3) [46]. Ex-
perimental data have demonstrated that the hypoxic
cells can be found around or in necrosis [47]. Due to
this, visible necrosis may serve as a surrogate marker for
intratumor hypoxia. Significant, positive correlation be-
tween necrotic TV (nTV) and TV was reported by
Kuhnt et al. He found that nTV based on CT scans was
significantly lower for controlled patients, than for those
with recurrent tumor (p = 0.003) in the group of patients
treated with RT alone. Tumors with smaller amount of ne-
crosis (<4 cm3) had a good prognosis regardless of the
type of treatment. Patients with tumors with a larger
amount of necrosis (≥4 cm3) had a significantly better out-
come if treated with CHRT as compared to RT alone [48].
Some data indicate that TV may reflect tumor type
and, in some way, general status of the patients. Rut-
kowski et al. found that T2 laryngeal tumors histologi-
cally poorly differentiated (G2,G3) presented with
significantly higher median TV compared to G1 tumors
(2.7 cm3 v 1.2 cm3, p = 0.001). Additionally, patients with
duration of disease symptoms prior to RT longer than 6
months had significantly lower median TV comparing to
others (1.6 cm3 v 3.8 cm3, p = 0.01). Significant, negative
correlation between TV and weight of the patients in this
group both, before and after RT was also reported [13].
Kats et al. investigated the association between TV,
that had been diagnosed on preoperative, diagnostic CT
scans, with pathologic evidence of thyroid cartilage
penetration in 94 patients who undergone total laryngec-
tomy due to cancer of the larynx. Among 49 nonira-
diated previously patients the mean TV of those with
and without thyroid cartilage penetration was 60.1 cm3
and 28 cm3 respectively (p = 0.004). When the nonirradi-
ated patients were divided into three TV groups
(<25 cm3, 25-50 cm3, >50 cm3) the rates of thyroid car-
tilage penetration were 23%, 17% and 78% respectively
(p = 0.003). No such correlation was found however for
patients previously irradiated. Additionally, when pa-
tients were divided by laryngeal subsites only supraglot-
tic tumors retained statistically significant association
between volume subgroup and thyroid cartilage penetra-
tion (p = 0.04). Authors recommended incorporation ofTV assessment into the diagnostic formula for predicting
thyroid cartilage penetration and selecting patients who
have a lower chance of benefiting from laryngeal preser-
vation [49].Conclusion
It is noticeable that considering TV, a single T stage
category cover tumors of various prognosis. Although it
is not possible to define general prognostic cut-off value
of TV for all HNC sites and stages, almost all of the clin-
ical data sets indicate its association with RT outcome.
The concept of significant influence of TV on RT results
is not new, but some innovative interpretation of it may
be employed in clinical practice at present. Progress in
tumor visualization techniques that are used for RT
planning facilitated TV evaluation. More accurate TV
estimation may serve as a additional predictor between
conventional RT alone, modern, highly conformal RT
techniques or more aggressive, combined treatment. In
any way, TV assessment should supplement clinical deci-
sion in the choice of optimal treatment strategy for
HNC patients.
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